FDA approved neratinib Feb. 25 in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
